drugset
drugset / Trial / NCT02661542

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

NCT02661542 ↗

Phase 1/2 Completed 106 enrolled Fujifilm Pharmaceuticals U.S.A., Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and Lymphomas. A total of up to 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD). Phase 2 will consist of 2 cohorts: Cohort 1 will include subjects with Pancreatic Cancer. Cohort 2 will include subjects with another tumor type enrolled in the Phase 1 dose-escalation phase who have demonstrated Clinical Benefit by Week 16.

Timeline

Start
2016-01
Primary completion
2020-11-05
Completion
2020-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject FF-10502-01 Unknown 8 mg/m2 Intravenous
Subject FF-10502-01 Unknown 12 mg/m2 Intravenous
Subject FF-10502-01 Unknown 18 mg/m2 Intravenous
Subject FF-10502-01 Unknown 27 mg/m2 Intravenous
Subject FF-10502-01 Unknown 40 mg/m2 Intravenous
Subject FF-10502-01 Unknown 60 mg/m2 Intravenous
Subject FF-10502-01 Unknown 90 mg/m2 Intravenous
Subject FF-10502-01 Unknown 100 mg/m2 Intravenous
Subject FF-10502-01 Unknown 135 mg/m2 Intravenous

Indications

cancer lymphoma